Taken together, our results indicate that non-viral engineering of anti-CD117 CAR T cells can lead to potent antitumor activity and complete eradication of HSPCs, envisioning its application prior to alloHSCT in early clinical trials of patients with high-risk AML or MDS. The gene discussed is KIT; the disease is acute myeloid leukemia.